Adocia SA announced the filing of a patent for an oral delivery technology of peptides. Peptides and proteins are widely used as drugs, especially in the treatment of chronic diseases such as diabetes. However, almost all these drugs are only available in injectable dosage forms, which represents a burden for patients and limits the adoption of these products, especially in chronic diseases that require numerous and regular injections. In recent years, intense research efforts have focused on developing oral dosage forms. However, there are considerable technological challenges as peptides are not naturally absorbed in the digestive tract and undergo significant degradation before entering the bloodstream. Adocia has developed a formulation which has demonstrated through preclinical studies an enhancement of the efficiency of peptide absorption by the digestive tract, making it possible to switch from injectable to oral dosage forms.